Page 14 - Access Pathway News Today

Provide innovators and developers of innovative products access to MHRA scientific expertise, regulatory guidance and an enhanced advice and signposting service.

After a single 25mg dose of COMP360 psilocybin therapy, approximately 30% of patients with treatment-resistant depression (TRD) were in remission at...

For people with early Alzheimers (MCI), HMTM treatment resulted in sustained improvement in cognition over pre-treatment baseline, and normalisat...

A wave of companies have been approved to test psychedelic therapies under new rules drawn up following departure from the EU

Kabir Nath will build upon COMPASS' success and lead the development of novel models of care to accelerate patient access to evidence-based innovation in mental health care George Goldsmith remains

Toronto, Ontario--(Newsfile Corp. - July 15, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Brussels is eyeing the UK’s post-Brexit approach to solving cell and gene therapy headaches.

14.06.2022 - Marketing authorization application is EQRx’s first submission to a regulatory agencyApplication is based on data from pivotal Phase 3 AENEAS trial in the first-line treatment of EGFR-mutated non-small cell lung cancer CAMBRIDGE, Mass., June 14, ... Seite 1

LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published researchSafety profile